The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i12.2582Keywords:
RSV, LRTI, Children, InfantAbstract
Respiratory syncytial virus (RSV) is the commonest cause of lower respiratory tract infection (LRTI) in children, particularly those aged <1 year. In South Africa (SA), increased hospitalisation rates during the RSV season, including access to intensive care facilities, place a huge burden on the healthcare system. Furthermore, RSV-LRTI during early childhood may lead to long-term respiratory sequelae, including recurrent wheezing, asthma, and impairment of lung function. Recently, two new RSV prevention strategies have emerged: nirsevimab, a long-acting monoclonal antibody, and a maternal RSV vaccine. Both strategies have shown high efficacy in reducing RSV-LRTI hospitalisation in infants and are being considered for licensure in SA. Implementation of these prevention strategies, combined with public engagement and collaboration between stakeholders, could significantly reduce RSV-related morbidity and mortality in SA.
References
1. Perin J, Mulick A, Yeung D, et al. Global, regional, and national causes of under-5 mortality in 2000-19: An updated systematic analysis with implications for the Sustainable Development Goals. Lancet Child Adolesc Health 2022;6(2):106-115. https://doi.org/10.1016/S2352-4642(21)00311-4
2. Bassat Q, Blau DM, Ogbuanu IU, et al. Causes of death among infants and children in the Child Health and Mortality Prevention Surveillance (CHAMPS) network. JAMA Netw Open 2023;6(7):e2322494. https://doi.org/10.1001/jamanetworkopen.2023.22494
3. Meissner HC. Viral bronchiolitis in children. N Engl J Med 2016;374(1):62-72. https://doi.org/10.1056/ NEJMra1413456
4. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015;372(9):835-845. https://doi.org/10.1056/NEJMoa1405870
5. Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia
requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study. Lancet 2019;394(10200):757-779. https://doi.org/10.1016/S0140- 6736(19)30721-4
6. Zar HJ, Barnett W, Stadler A, Gardner-Lubbe S, Myer L, Nicol MP. Aetiology of childhood pneumonia in a well vaccinated South African birth cohort: A nested case-control study of the Drakenstein Child Health Study. Lancet Respir Med 2016;4(6):463-472. https://doi.org/10.1016/S2213-2600(16)00096-5
7. Von Mollendorf C, Berger D, Gwee A, et al. Aetiology of childhood pneumonia in low- and middle- income countries in the era of vaccination: A systematic review. J Glob Health 2022;12:10009. https:// doi.org/10.7189/jogh.12.10009
8. Taleb SA, Al Thani AA, Al Ansari K, Yassine HM. Human respiratory syncytial virus: Pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis 2018;37(10):1817- 1827. https://doi.org/10.1007/s10096-018-3289-4
9. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape. Lancet Infect Dis 2023;23(1):e2-e21. https://doi.org/10.1016/ S1473-3099(22)00291-2
10. Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to respiratory syncytial virus: Burden and risk factors. Am J Respir Crit Care Med 2017;195(1):96-103. https://doi.org/10.1164/rccm.201603- 0658OC
11. Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010;65(12):1045-1052. https://doi.org/10.1136/ thx.2009.121582
12. Armarego M, Forde H, Wills K, Beggs SA. High-flow nasal cannula therapy for infants with bronchiolitis. Cochrane Database Systematic Rev 2024;3:CD009609. https://doi.org/10.1002/14651858. CD009609.pub3.
13. Shahabi A, Peneva D, Incerti D, McLaurin K, Stevens W. Assessing variation in the cost of palivizumab for respiratory syncytial virus prevention in preterm infants. Pharmacoecon Open 2018;2(1):53-61. https://doi.org/10.1007/s41669-017-0042-3
14. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic VV, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013, Issue 4. Art. No.: CD006602. https://doi.org/10.1002/14651858.CD006602.pub4
15. Gonzales T, Bergamasco A, Cristarella T, et al. Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: A systematic review. Am J Perinatol 2024;41(S 01):e1107-e1115. https://doi.org/10.1055/a-1990-2633
16. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020;383(5):415-425. https://doi.org/10.1056/NEJMoa1913556
17. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022;386(9):837-846. https://doi.org/10.1056/NEJMoa2110275
18. Muller WJ, Madhi SA, Nuñez BS, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med 2023;388(16):1533-1534. https://doi.org/10.1056/NEJMc2214773
19. Riccò M, Cascio A, Corrado S, et al. Impact of nirsevimab immunization on pediatric hospitalization rates: A systematic review and meta-analysis (2024). Vaccines (Basel) 2024;12(6):640. https://doi. org/10.3390/vaccines12060640
20. Assad Z, Romain AS, Aupiais C, et al. Nirsevimab and hospitalization for RSV bronchiolitis. N Engl J Med 2024;391(2):144-154. https://doi.org/10.1056/NEJMoa2314885
21. Ares-Gómez S, Mallah N, Santiago-Pérez MI, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: Initial results of a population-based longitudinal study. Lancet Infect Dis 2024;24(8):817-828. https:// doi.org/10.1016/S1473-3099(24)00215-9
22. Koltai M, Moyes J, Nyawanda B, et al. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa. BMC Med 2023;21(1):120. https://doi.org/10.1186/s12916-023-02806-w
23. Etti M, Calvert A, Galiza E, et al. Maternal vaccination: A review of current evidence and recommendations. Am J Obstet Gynecol 2022;226(4):459-474. https://doi.org/10.1016/j.ajog.2021.10.041 24. Cumberland P, Shulman CE, Maple PA, et al. Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis
2007;196(4):550-557. https://doi.org/10.1086/519845
25. Scott S, Cumberland P, Shulman CE, et al. Neonatal measles immunity in rural Kenya: The influence
of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in
maternal and cord serum samples. J Infect Dis 2005;191(11):1854-1860. https://doi.org/10.1086/429963 26. Madhi SA, Polack FP, Piedra PA, et al. Respiratory syncytial virus vaccination during pregnancy and
effects in infants. N Engl J Med 2020;383(5):426-439. https://doi.org/10.1056/NEJMoa1908380
27. DieussaertI,HyungKimJ,LuikS,etal.RSVprefusionFprotein-basedmaternalvaccine–pretermbirth
and other outcomes. N Engl J Med 2024;390(11):1009-1021. https://doi.org/10.1056/NEJMoa2305478 28. Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023;388(16):1451-1464. https://doi.org/10.1056/NEJMoa2216480 29. Moro PL. Maternal RSV vaccine safety surveillance. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, Ga., 26-28 June 2024. https://stacks.cdc.gov/view/cdc/157873
(accessed 18 September 2024).
30. Nyawanda BO, Otieno NA, Otieno MO, et al. The impact of maternal human immunodeficiency
virus infection on the burden of respiratory syncytial virus among pregnant women and their infants,
western Kenya. J Infect Dis 2022;225(12):2097-2105. https://doi.org/10.1093/infdis/jiaa490
31. Dauby N, Gagneux-Brunon A, Martin C, Mussi-Pinhata MM, Goetghebuer T. Maternal immunization in women living with HIV. AIDS 2024;38(2):137-144. https://doi.org/10.1097/QAD.0000000000003758 32. World Health Organization. Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 23 - 26 September 2024. WHO. https://www.who.int/groups/strategic- advisory-group-of-experts-on-immunization/#:~:text=The%20Strategic%20Advisory%20Group%20
of%20Experts
33. Zar HJ, Piccolis M, Terstappen J, et al. Access to highly effective long-acting RSV-monoclonal
antibodies for children in LMICs – reducing global inequity. Lancet Glob Health 2024 (epub 24 July 2024). https://doi.org/10.1016/S2214-109X(24)00258-4
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Z Dangor, S A Madhi, H Zar, D Demopoulos
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
